Arcion gets $8.8M in VC

CMEA Ventures and InterWest Partners have led an $8.8 million A round for Arcion Therapeutics. Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy. Arcion also has gels in development for other pain indications, looking to compete in the sector by offering a new therapy with fewer side effects.

- see this release for more

Suggested Articles

Pfizer has signed up for a new three-year deal, with the option for this to be extended to five years, with CRO Syneos Health.

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.